Lowey Dannenberg is investigating Allakos, Inc. (“Allakos” or the “Company”) (NASDAQ: ALLK) and certain of its officers and/or directors for potential violation of federal securities laws or other unlawful business practices in connection with Allakos’ development of AK002, a drug for the treatment of certain gastrointestinal diseases.